The dimethylrnethylene blue (DMB)-based screening procedure for mucopolysaccharidosist-' and the alcian blue' (AB)-based procedure both measure glycosaminoglycan (GAG) content directly in urine. We compared the two procedures. Absorbance per microgram of GAG for DMB was 25 times that obtained with AB, resulting in a requirement for 10 times smaller sample volumes for the former. Recoveries of added heparan sulphate for the AB assay in the absence and presence of added protein (2' 5 giL) were comparable (78-95% and 75-111 070), as was the case with the DMB assay. Here, recoveries were generally better (94-103% and 96-100%). The coefficient of correlation (CC) between the two methods measured on 86 reference urine samples was O'861. For mucopolysaccharidosis urines the CC was higher (0'928). Age-dependent reference values were comparable. Performance of the assays was compared by measurement of GAG content in 24 mucopolysaccharidosis urines. Standard deviation scores (measured value minus mean of reference values divided by standard deviation in reference values) and probabilities for classification in the patient group were calculated and compared. Especially for urines from patients with less distinctly increased GAG content (Sanfilippo, Scheie), scores and probabilities were higher with the DMB assay.
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The mucopolysaccharidoses (MPS) are a group of lysosomal diseases characterized by a deficiency of one of the lysosomal enzymes involved in the degradation of glycosaminoglycans (GAG). All known mucopolysaccharidoses give rise to an increased urinary GAG content. Quantitative measurement of GAG in urine can therefore, be used as a screening procedure for all MPS. The prevalence of the whole group of these monogenic disorders is 1:25' 000. 4 We described a simple and reliable screening procedure based on dimethylmethylene blue (DMB), which appeared simpler and more reliable than existing quantitative! and qualitative! methods. A modification of the method made it insensitive to urinary protein.? Spectrophotometric measurement was made on untreated urine directly after addition of the reagent. Two procedures for measurement of urinary GAGs Correspondence: Dr J G N de Jong. based on alcian blue (AB) have been described. The method described by Whiteman et al. 6 is based on precipitation of AB-GAG complexes. Gold 3 , ? described a method based on AB for direct measurement on untreated urines. Dembure et al. 8 described the use of this method, after precipitation of GAGs from urine, as a screening procedure for MPS. This AB assay iS,like our DMB assay, not dependent on precipitation, which can be incomplete as is described for precipitation of low molecular mass glycosaminoglycans (mol. wt < 3000) with cetylpyridinium chloride.P We have compared the DMB and AB procedures especially with respect to sensitivity and ability to discriminate between non-MPS and MPS urines.
MATERIALS AND METHODS
A1cian blue assay The original AB assay was carried out under alkaline conditions." In the modified procedure, a more stable acidic dye solution is used which gave more stable GAG-AB complexes and permitted the estimation of GAG in the presence of other polyanions.! In our hands, none of the AB products obtained from various firms gave stable solutions with the basic reagent. For the preparation of the AB reagent, AB was dissolved in 15070 phosphoric acid and 2% sulphuric acid in a concentration of 1 giL and filtered. We did this for seven different AB products obtained from various firms and measured the absorbance (spectrophotometric) and turbidity (nephelometric) with and without added heparan sulphate (HS). Only two of them (Serva AB analytical grade No. 12020 and Sigma AB 8GX No. A5268) gave acceptable absorbances at 480 nm and increases in absorbance after addition of HS without measurable turbidity. The Serva product (Serva Feinbiochemica GmbH, Heidelberg, Germany) was used in this investigation. To 180 ILL heparan sulphate (Sigma Chemical Company, St Louis, MO, USA, No. H9637) standard solution or urine sample 220ILL AB reagent was added. Absorbance was measured 120 s after addition at 480 nm and 25°C in a Cobas Fara analyser (Hofmann-La Roche & Co. AG, Basel, Switzerland). For the calibration curve 18, 36, 54, 72, 108 and 144 mg/L standard solutions were used. Measured absorbance was corrected for reagent and sample blank.
Dimethylmethylene blue assay Measurements were performed as described elsewhere.! In short, to 20 ILL (series 1), 10 ILL (series 2) and 5 ILL (series 3) of standard or urine sample were added 275 ILL DMB (Serva, research grade No. 20335) solution (28 mM DMB, 50 mM formic acid and 0·18 M Tris, pH 8'8) . This DMB quality is no longer available. We tested seven different DMB products obtained from various firms. Only three of them gave absorbances at peak values without HS (591 nm) and with HS (520 nm) that were in a range comparable with Serva DMB. For the other four products there were problems with respect to linearity. Aldrich DMB nr 34,108-8 (dye content =90%) gave the highest absorbance values, comparable with that of Serva DMB and can therefore be used instead. The standard concentrations used were 18, 36, 54 mg/L HS for series 1 (measurement range: 18-36); 36, 72, 108 mg/L HS for series 2 (measurement range 36-72); and 72, 144, 216 mg/L HS for series 3 (measurement range 72-216). Corrections were made for reagent blank and sample blank. Measurements were made at Ann Clin Biochem 1994: 31 520 nm and 25°C 5 s after addition of the DMB reagent in the Cobas Fara analyser.
Urine specimens MPS urines and reference urines were untimed urine specimens. MPS patients diagnosed on the basis of clinical symptoms and enzyme deficiencies in leukocytes and/or fibroblasts could be subdivided on the basis of the defective enzyme in the respective mucopolysaccharidoses (two Hurler, three Scheie, one Hunter, 10 Sanfilippo type A, five Sanfilippo type B, two Morquio type A and one Maroteaux-Lamy). Reference urines were from patients not suffering from mucopolysaccharidosis, and sent to our laboratory for screening for metabolic diseases.
Statistical methods
Standard deviation scores (SDS) were calculated by dividing the difference between the observed patient value and the age-related mean reference value by the corresponding standard deviation.'
Probabilities for classification in the patient group were calculated by discriminant analysis. Data for controls were fitted according to the formula:
where In(DMB) and In(AB) are the natural logarithms of measured values for controls with the DMB and AB assay, respectively. Exp( -0 '12 X age) is the ( -0·12 x age)th power of the mathematical constant e. Residuals appeared to be normally distributed. Procedure DISCRIM from the SAS-package (SAS Institute Inc., Cary, NC, USA) was used to compute for patients the individual probabilities for membership in the group of patients by discriminant analysis.
RESULTS AND DISCUSSION
From the calibration curves an absorbance of 9·8 mAbs/ILg HS was measured for the AB assay. For DMB this value was 24· 6 times higher (242 mAbslILg). Therefore the DMB assay is much more sensitive and a smaller sample volume is needed for the assay. The large sample volume needed for the AB assay makes it more sensitive to interfering substances. The between-run coefficient of variation estimated by measurement of a urine sample in 10 different runs was 4% for the DMB and 11% for the AB assay. The latter value is within the range of variation coefficients in age-dependent reference values (Table 1) . The influence of protein on the AB assay was tested by measuring the recovery of HS (36 mg/L) added to four different urines with and without added human serum albumin (2' 5 giL). Recoveries without protein (78070-95070) and with protein (76% -111 %) for AB were comparable. 
Standard deviation scores and probabilities
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For the DMB assay these values were, respectively, 94%-103% and 96%-100%. From this we concluded that the AB assay is, like the DMB assay, not sensitive to protein.
There was a good correlation for 86 non-MPS urines between the AB and DMB assays ([AB] = 1'055 [DMB] -0-029; r=0·861). For 24 MPS urines we found: [AB] = 1'126[DMB] +6·225 (r=0·928). The correlation for MPS urines was better than for the reference urines, probably due to the higher GAG concentrations in these urines. The influence of interfering compounds will be relatively smaller. The means and standard deviations of the reference values, expressed as milligrams of GAG per mmol creatinine, for the various age categories in a total of 86 non-MPS urines were comparable ( significant discrepancy from normal the SDS value must always be higher than two. In Table  2 SDS data are given in order of increasing AB SDS values. The median SDS value for the DMB method (18' 2) was significantly higher than for the AB method (8'5) . Sixteen of 24 DMB SDS values were higher than AB SDS values. Most important, however, is that in the lower SDS range, that is in urines with less distinct increases in GAG content, DMB SDS values are significantly higher than those measured with the AB test procedure. Individual probabilities, calculated by discriminant analysis for correct classification in the patient group for both procedures are given in Table 2 . Although both the DMB and AB assay classified all patients correctly, probabilities for AB were lower than for DMB data, again for urines with less distinct increases in GAG content. Seven MPS urines measured by the AB procedure gave probabilities lower than O·95. With the DMB assay one urine with a probability lower than O·95 was found. A graphical presentation of patient data and those obtained from a series of reference urines as a function of age for the DMB and AB assays are given in Fig. 1 .
The DMB assay has a higher sensitivity, and the smaller sample volume needed probably makes it less sensitive to interfering substances; it also shows a better discriminatory power between MPS and normal urines. It is concluded that the DMB assay is better suited for urinary screening for mucopolysaccharidoses than the AB assay.
